Can I read Antimuscarinics for Neurogenic Overactive Bladder in Multiple Sclerosis: Real-life Data on EtoBox?

Antimuscarinics for Neurogenic Overactive Bladder in Multiple Sclerosis: Real-life Data by Elena Andretta; Enrico Finazzi Agrò; Massimiliano Calabrese; Luca Orecchia; Antonietta Furlan; Cristina Zuliani is a Medicine article available to read on EtoBox.

What is Antimuscarinics for Neurogenic Overactive Bladder in Multiple Sclerosis: Real-life Data about?

## Background: Antimuscarinics (AMs) represent the mainstay of treatment for storage lower urinary tract symptoms (LUTS) but few data are available on their impact in multiple sclerosis (MS) patients. ## Objective: To assess effectiveness and tolerability of AMs in MS patients with neurogenic detrusor overactivity (NDO). ## Methods: Sixty consecutive outpatients, who started treatment with AMs at one centre, were recruited. The primary endpoint was change in Patient’s Perception of Intensity of Urgency Scale (PPIUS) at 6 months; secondary endpoints were post-void residual urine (PVR) and pads used daily. Incidence and severity of adverse events (AEs) were recorded. ## Results: Significant reduction (__p__ < 0.001) of mean PPIUS and pads use were detected, as well as a significant increase (__p__ < 0.001) of PVR (143 ± 42 ml). AEs, recorded in 53% of patients, were frequently multiple and caused suspension of AM in 10% of cases, mainly for xerostomia, which has been the commonest AE (26.6%). Neurological AEs appeared in 11.7% of subjects, mostly with oxybutynin. Worsening/onset of voiding LUTS, reported by 8.3% of MS, resulted to be the unique AE correlated to AM dosage. ## Conclusi

Who reads Antimuscarinics for Neurogenic Overactive Bladder in Multiple Sclerosis: Real-life Data?

Author

Elena Andretta; Enrico Finazzi Agrò; Massimiliano Calabrese; Luca Orecchia; Antonietta Furlan; Cristina Zuliani

Publisher

SAGE Publications

Published

2022

Language

EN

Field

Medicine (Health Sciences)